Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria

Journal of Immunology

Volumn 178, Issue 8, 2007, Pages 5312-5320

  Wang, Xianxi ^a   Meng, Xiaomei ^a   Kuhlman, Joshua R ^a   Nelin, Leif D ^a,c   Nicol, Kathleen K ^b,c   English, B Keith ^d   Liu, Yusen ^a,c  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOTEICHOIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NITRIC OXIDE; PEPTIDOGLYCAN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME ACTIVATION; GENE; GRAM POSITIVE BACTERIUM; INFLAMMATION; INNATE IMMUNITY; KNOCKOUT MOUSE; MACROPHAGE; MKP1 GENE; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STAPHYLOCOCCUS INFECTION; SURVIVAL;

EID: 34247142019     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.8.5312     Document Type: Article

References (47)

1. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554.
2. Wang, J. E., M. K. Dahle, A. Yndestad, I. Bauer, M. C. McDonald, P. Aukrust, S. J. Foster, M. Bauer, A. O. Aasen, and C. Thiemermann. 2004. Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat. Crit. Care Med. 32: 546-552.
3. Thiemermann, C. 2002. Interactions between lipoteichoic acid and peptidoglycan from Staphylococcus aureus: a structural and functional analysis. Microbes Infect. 4: 927-935.
4. Todd, J. K. 2005. Staphylococcal infections. Pediatr. Rev. 26: 444-450.
5. Herold, B. C., L. C. Immergluck, M. C. Maranan, D. S. Lauderdale, R. E. Gaskin, S. Boyle-Vavra, C. D. Leiten, and R. S. Daum. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. J. Am. Med. Assoc. 279: 593-598.
6. Centers for Disease Control and Prevention. 1999. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. J. Am. Med. Assoc. 282: 1123-1125.
7. Frank, A. L., J. F. Marcinak, P. D. Mangat, and P. C. Schreckenberger. 1999. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr. Infect. Dis. J. 18: 993-1000.
8. Buckingham, S. C., L. K. McDougal, L. D. Cathey, K. Comeaux, A. S. Craig, S. K. Fridkin, and F. C. Tenover. 2004. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee Children's Hospital. Pediatr. Infect. Dis. J. 23: 619-624.
9. Gonzalez, B. E., G. Martinez-Aguilar, K. G. Hulten, W. A. Hammerman, J. Coss-Bu, A. Avalos-Mishaan, E. O. Mason, Jr., and S. L. Kaplan. 2005. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 115: 642-648.
10. Parrillo, J. E. 1993. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328: 1471-1477.
11. Medzhitov, R., and C. Janeway, Jr. 2000. The Toll receptor family and microbial recognition. Trends Microbiol. 8: 452-456.
12. Kengatharan, K. M., S. De Kimpe, C. Robson, S. J. Foster, and C. Thiemermann. 1998. Mechanism of Gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J. Exp. Med. 188: 305-315.
13. De Kimpe, S. J., M. Kengatharan, C. Thiemermann, and J. R. Vane. 1995. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc. Natl. Acad. Sci. USA 92: 10359-10363.
14. Carl, V. S., K. Brown-Steinke, M. J. Nicklin, and M. F. Smith, Jr. 2002. Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages. J. Biol. Chem. 277: 17448-17456.
15. Wang, J. E., P. F. Jorgensen, M. Almlof, C. Thiemermann, S. J. Foster, A. O. Aasen, and R. Solberg. 2000. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor α, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect. Immun. 68: 3965-3970.
16. Philpott, D. J., and S. E. Girardin. 2004. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol. Immunol. 41: 1099-1108.
17. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11: 443-451.
18. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, and D. Golenbock. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163: 1-5.
19. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C. J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J. Biol. Chem. 274: 17406-17409.
20. Janeway, C. A. J., P. Travers, M. Walport, and M. J. Shlomchik. 2001. Immunobiology: The Immune System in Health and Disease, 5th Ed. Garland Publishing, New York.
21. Suffredini, A. F., G. Fantuzzi, R. Badolato, J. J. Oppenheim, and N. P. O'Grady. 1999. New insights into the biology of the acute phase response. J. Clin. Immunol. 19: 203-214.
22. Kumar, A., A. Krieger, S. Symeoneides, A. Kumar, and J. E. Parrillo. 2001. Myocardial dysfunction in septic shock. Part II. Role of cytokines and nitric oxide. J. Cardiothorac. Vasc. Anesth. 15: 485-511.
23. Dong, C., R. J. Davis, and R. A. Flavell. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20: 55-72.
24. Lee, J. C., S. Kassis, S. Kumar, A. Badger, and J. L. Adams. 1999. p38 Mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther. 82: 389-397.
25. Kontoyiannis, D., M. Pasparakis, T. T. Pizarro, F. Cominelli, and G. Kollias. 1999. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10: 387-398.
26. Dumitru, C. D., J. D. Ceci, C. Tsatsanis, D. Kontoyiannis, K. Stamatakis, J. H. Lin, C. Patriotis, N. A. Jenkins, N. G. Copeland, G. Kollias, and P. N. Tsichlis. 2000. TNF-α induction by LPS is regulated posttranscriptionally via a Tp12/ERK-dependent pathway. Cell 103: 1071-1083.
27. Keyse, S. M. 2000. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12: 186-192.
28. Shepherd, E. G., Q. Zhao, S. E. Welty, T. N. Hansen, C. V. Smith, and Y. Liu. 2004. The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages. J. Biol. Chem. 279: 54023-54031.
29. Zhao, Q., X. Wang, L. D. Nelin, Y. Yao, R. Malta, M. E. Manson, R. S. Baliga, X. Meng, C. V. Smith, J. A. Bauer, et al. 2006. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 203: 131-140.
30. Hammer, M., J. Mages, H. Dietrich, A. Servatius, N. Howells, A. C. Cato, and R. Lang. 2006. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J. Exp. Med. 203: 15-20.
31. Salojin, K. V., I. B. Owusu, K. A. Millerchip, M. Potter, K. A. Platt, and T. Oravecz. 2006. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J. Immunol. 176: 1899-1907.
32. Chi, H., S. P. Barry, R. J. Roth, J. J. Wu, E. A. Jones, A. M. Bennett, and R. A. Flavell. 2006. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc. Natl. Acad. Sci. USA 103: 2274-2279.
33. English, B. K., E. M. Maryniw, A. J. Talati, and E. A. Meals. 2006. Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob. Agents Chemother. 50: 2225-2227.
34. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27: 493-497.
35. Chen, P., J. Li, J. Barnes, G. C. Kokkonen, J. C. Lee, and Y. Liu. 2002. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169: 6408-6416.
36. Liu, Y., M. Gorospe, C. Yang, and N. J. Holbrook. 1995. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress: inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. J. Biol. Chem. 270: 8377-8380.
37. Vieillard-Baron, A., S. Prin, K. Chergui, O. Dubourg, and F. Jardin. 2003. Hemodynamic instability in sepsis: bedside assessment by Doppler echocardiography. Am. J. Respir. Crit. Care Med. 168: 1270-1276.
38. Klebanoff, S. J. 2005. Myeloperoxidase: friend and foe. J. Leukocyte Biol. 77: 598-625.
39. Sun, H., C. H. Charles, L. F. Lau, and N. K. Tonks. 1993. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75: 487-493.
40. Sun, H., N. K. Tonks, and D. Bar-Sagi. 1994. Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science 266: 285-288.
41. Franklin, C. C., and A. S. Kraft. 1997. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J. Biol. Chem. 272: 16917-16923.
42. Zhang, Y., J. N. Blattman, N. J. Kennedy, J. Duong, T. Nguyen, Y. Wang, R. J. Davis, P. D. Greenberg, R. A. Flavell, and C. Dong. 2004. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 430: 793-797.
43. Matsuguchi, T., T. Musikacharoen, T. R. Johnson, A. S. Kraft, and Y. Yoshikai. 2001. A novel mitogen-activated protein kinase phosphatase is an important negative regulator of lipopolysaccharide-mediated c-Jun N-terminal kinase activation in mouse macrophage cell lines. Mol. Cell. Biol. 21: 6999-7009.
44. Jeffrey, K. L., T. Brummer, M. S. Rolph, S. M. Liu, N. A. Callejas, R. J. Grumont, C. Gillieron, F. Mackay, S. Grey, M. Camps, et al. 2006. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat. Immunol. 7: 274-283.
45. Kerr, A. R., J. J. Irvine, J. J. Search, N. A. Gingles, A. Kadioglu, P. W. Andrew, W. L. McPheat, C. G. Booth, and T. J. Mitchell. 2002. Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect. Immun. 70: 1547-1557.
46. Rijneveld, A. W., S. Florquin, T. Hartung, P. Speelman, and P. T. van der. 2003. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J. Infect. Dis. 188: 282-285.
47. Nau, R., and H. Eiffert. 2002. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin. Microbiol. Rev. 15: 95-110.